Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

Results: Efficacy Primary endpoint: Pooled D3 and D5      Pooled D3and D5 Nolasiban PlaceboIncreasep 900 mg n390388 Ongoing pregnancyrateat28.5%35.6%7.1%0.031 10 weeks Absolute 7.1% increase compared to placebo Relative 25% increase compared to placebo